MYCOBUTIN 150 MG — DIN 02063786
RIFABUTIN : 150 MG · PFIZER CANADA ULC · CAPSULE · wholesale supply in Canada
Health Canada status: MARKETED
What is MYCOBUTIN?
MYCOBUTIN 150 MG contains RIFABUTIN : 150 MG. It is listed in the Health Canada Drug Product Database under DIN 02063786, held by PFIZER CANADA ULC, supplied as CAPSULE for ORAL administration. Health Canada currently lists it as marketed, status dated 16-Feb-2005. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is MYCOBUTIN used for?
MYCOBUTIN (rifabutin) is indicated for the prevention of disseminated Mycobacterium avium complex (MAC) disease in patients with advanced HIV infection (CD4+ cell count ≤200/mm³ with an AIDS defining diagnosis, or CD4+ cell count ≤ 100/mm³ without an AIDS defining diagnosis). To reduce the development of drug-resistant bacteria and maintain the effectiveness of MYCOBUTIN and other antibacterial drugs, MYCOBUTIN should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Rifabutin cost around the world?
Rifabutin is listed on 3 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; South Africa publishes a single exit price; United States publishes a acquisition. Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| United States | acquisition | 1 | 3 | USD███.██ |
| Australia | ex-manufacturer | 1 | 2 | AUD███.██ |
| South Africa | single exit price | 1 | 1 | ZAR███.██ |
6 pack listings across 3 brand entries and 3 price bases, refreshed 08 Sep 2026. Ranges span every Rifabutin pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 150 MG |
|---|---|
| Dosage form | CAPSULE |
| Route | ORAL |
| Pack configuration (monograph) | MYCOBUTIN (rifabutin) is supplied as hard gelatin capsules having an opaque red-brown cap and body, imprinted with PHARMACIA & UPJOHN/ MYCOBUTIN, in white ink, each containing 150 mg rifabutin. |
| Storage | Store at controlled room temperature, 15°C-30 °C. Keep container tightly closed. Keep out of reach and sight of children. |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Rifabutin |
|---|---|
| ATC code | J04AB04 |
| AHFS class | 08:16.04 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02063786 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2063786 |
| Brand name | MYCOBUTIN |
| Generic / active ingredient | RIFABUTIN : 150 MG |
| Market authorization holder | PFIZER CANADA ULC |
| Health Canada schedule | Prescription |
| ATC code | J04AB04 |
| ATC anatomical main group | J — Anti-infectives for systemic use |
| ATC therapeutic subgroup | J04AB |
| Current status | MARKETED |
| Status date | 16-Feb-2005 |
| Original market date | 1995-12-31 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
It is recommended that MYCOBUTIN (rifabutin) 300 mg be administered once daily with or without food. For those patients who experience nausea, vomiting or other gastrointestinal upsets, it may be useful to split the MYCOBUTIN dose in half (one 150 mg capsule) twice a day with food. The capsule(s) should be swallowed whole with a drink of water. If a dose is missed, the patient should take the dose as soon as remembered. If it is almost time for the next dose, the patient should skip the missed dose and take the next dose at the regularly scheduled time. Do not double the dose.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Concomitant use with rilpivirine containing prolonged-release suspension for injection is contraindicated. MYCOBUTIN is contraindicated in patients who are hypersensitive to this drug or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container. For a complete listing, see 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING.
Warnings and precautions
MYCOBUTIN (rifabutin) prophylaxis must not be administered to patients with active tuberculosis. Patients who develop signs and symptoms consistent with active tuberculosis while on MYCOBUTIN prophylaxis should be evaluated immediately. Administration of MYCOBUTIN, as a single-agent, to patients with active tuberculosis is likely to lead to the development of tuberculosis which is resistant both to MYCOBUTIN and to rifampin. There is no evidence that MYCOBUTIN provides effective prophylaxis against M. tuberculosis infections. Patients requiring prophylaxis against both M. tuberculosis and Mycobacterium avium complex may be given isoniazid and MYCOBUTIN concurrently. Significant drug-drug interactions between rifabutin and protease inhibitors, among many other drugs, requires careful consideration. Patients should be carefully monitored to avoid uveitis. If uveitis is suspected, the patient should be referred to an ophthalmologist and, if considered necessary, treatment with MYCOBUTIN should be suspended. Rifabutin is a CYP450 3A inducer. Therefore, co-administration with antiretroviral products including but not limited to bictegravir, elvitegravir/Cobicistat, oral rilpivirine, or doravirine and anti-HCV products including but not limited to sofosbuvir (alone or in combination) is not recommended due to the expected decrease in plasma concentrations of the antiretrovirals and anti-HCV products which may lead to loss of virologic response and possible development of resistance. Anaphylactic shock has occurred with other antibiotics of the same class. Clostridium difficile-associated disease (CDAD) has been reported with use of many antibacterial agents, including MYCOBUTIN (rifabutin). CDAD may range in severity from mild diarrhea to fatal colitis. It is important to consider this diagnosis in patients who present with diarrhea, or symptoms of colitis, pseudomembranous colitis, toxic megacolon, or perforation of colon subsequent to the administration of any antibacterial agent. If the diagnosis of CDAD is suspected or confirmed, appropriate therapeutic measures should be initiated. Severe cutaneous adverse reactions (SCARs), such as Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), and acute generalized exanthematous pustulosis (AGEP) have been reported with anti-tuberculosis drugs. If patients develop a skin rash they should be monitored closely and suspect drug(s) discontinued if lesions progress.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
2 · Same class — other molecules in ATC J04AB
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Rifampicin | RIFADIN · RIFADIN CAP 300MG · ROFACT | 5 | 2 | Yes |
| Rifabutin | MYCOBUTIN | 1 | 1 | Yes |
| Capreomycin | CAPASTAT PWS IM 1G VIAL | 1 | 0 | Not in Canada |
| Cycloserine | SEROMYCIN CAP 250MG | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC J04A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| J04AC | Isoniazid · Isoniazid, Combinations | 19 | 3 |
| J04AK | Ethambutol · Pyrazinamide | 8 | 3 |
| J04AA | Sodium Aminosalicylate | 1 | 0 |
| J04AM | Rifampicin, Pyrazinamide And Isoniazid | 1 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is MYCOBUTIN called?
Also recorded in Canada as: rifabutin 150 MG Oral Capsule [Mycobutin] (US), amoxicillin 250 MG / omeprazole 10 MG / rifabutin 12.5 MG Delayed Release Oral Capsule [Talicia] (US), rifabutin 150 MG Oral Capsule (US), amoxicillin 250 MG / omeprazole 10 MG / rifabutin 12.5 MG Delayed Release Oral Capsule (US), OMEPRAZOLE MAGNESIUM, AMOXICILLIN AND RIFABUTIN (US), RIFABUTIN (US), Rifabutin (GLOBAL), Rifabutin (UK), Ributin (IN), Montabutin (IN).
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.